| 2025-03-31 | +1.78 % |
|
| 2025-03-28 | -1.2 % |
|
| 2025-03-27 | +0.33 % |
|
| 2025-03-25 | -0.73 % |
|
| 2025-03-21 | -0.64 % |
|
| 2025-03-20 | -0.42 % |
|
| 2025-03-18 | -2 % |
|
| 2025-03-17 | +0.26 % |
|
| 2025-03-14 | +2.02 % |
|
| 2025-03-11 | -4.58 % |
|
| 2025-03-10 | +1.8 % |
|
| 2025-03-07 | +3.29 % |
|
| 2025-03-06 | +0.54 % |
|
| 2025-03-05 | -3.3 % |
|
| 2025-03-04 | -0.69 % |
|
| 2025-03-03 | -0.18 % |
|
| 2025-02-27 | -1.42 % |
|
| 2025-02-24 | -0.88 % |
|
| 2025-02-19 | +1.7 % |
|
| 2025-02-14 | -2.71 % |
|
| 2025-02-13 | +1.22 % |
|
| 2025-02-12 | -0.35 % |
|
| 2025-02-11 | -0.47 % |
|
| 2025-02-10 | +0.68 % |
|
| 2025-02-07 | -0.1 % |
|
| 2025-02-06 | -2.23 % |
|
| 2025-02-05 | +0.88 % |
|
| 2025-02-04 | -0.04 % |
|
| 2025-02-03 | +1.85 % |
|
| 2025-01-31 | -8.33 % |
|
| 2025-01-30 | +1.89 % |
- ResMed (RMD) stock rose by 1.89% due to positive market sentiments surrounding expected fiscal measures in the upcoming Union Budget 2025, which are anticipated to boost economic growth and consumer spending, reflecting wider optimism in the stock market.
- The article discusses the calm in global stock markets and highlights the mixed reactions to major tech earnings, noting that ResMed (RMD) stock rose by 1.89% amid broader market trends and speculation surrounding monetary policy and corporate results.
ResMed (RMD) stock likely increased due to positive market sentiment stemming from expected stable Federal Reserve policies and anticipation of favorable market conditions influenced by upcoming economic data releases.
- ResMed (RMD) stock rose by 1.89% to reach a four-year high of $40.75 amidst a day when the S&P/ASX 200 Index reached a new record, with several other shares also hitting multi-year peaks despite a lack of specific company news, indicating overall market optimism.
- ResMed Inc. (NYSE: RMD) saw a 1.89% increase in stock price due to impressive second quarter fiscal year 2025 results highlighted by a 10% revenue growth, margin expansion, and strong cash flow from increased demand for its sleep and breathing health products, as well as digital health solutions.
- ResMed (RMD) stock rose by 1.89% amid broader market optimism driven by the anticipation of positive developments from the upcoming Union Budget 2025, which is expected to focus on boosting consumption, infrastructure spending, and job creation.
|
| 2025-01-29 | +1.17 % |
|
| 2025-01-28 | -1.87 % |
|
| 2025-01-21 | +3.34 % |
|
| 2025-01-17 | +1.12 % |
|
| 2025-01-16 | +1.61 % |
|
| 2025-01-15 | +1.99 % |
|
| 2025-01-14 | -0.62 % |
|
| 2025-01-10 | -1 % |
|
| 2025-01-08 | -0.1 % |
|
| 2025-01-07 | +0.56 % |
|
| 2024-12-30 | -1.58 % |
|
| 2024-12-23 | -2.57 % |
|
| 2024-12-20 | +2.46 % |
|
| 2024-12-18 | -5.11 % |
|
| 2024-12-17 | +0.66 % |
|
| 2024-12-16 | +1.05 % |
|
| 2024-12-13 | -1.65 % |
|
| 2024-12-10 | +0.19 % |
|
| 2024-12-09 | +1.39 % |
|
| 2024-12-06 | +0.84 % |
|
| 2024-12-05 | -2.62 % |
|
| 2024-11-26 | +0.17 % |
|
| 2024-11-25 | +2.37 % |
|
| 2024-11-21 | +0.85 % |
|
| 2024-11-18 | +1.99 % |
|
| 2024-11-15 | +1.43 % |
|
| 2024-11-13 | -4.76 % |
|
| 2024-11-08 | +1.55 % |
|
| 2024-11-07 | +1.18 % |
|
| 2024-11-05 | +0.87 % |
|
| 2024-11-01 | +0.75 % |
|
| 2024-10-31 | -0.23 % |
|
| 2024-10-29 | -0.98 % |
|
| 2024-10-28 | -3.61 % |
|
| 2024-10-24 | +0.7 % |
|
| 2024-10-17 | +0.52 % |
|
| 2024-10-16 | -0.35 % |
|
| 2024-10-15 | -0.64 % |
|
| 2024-10-14 | +0.08 % |
|
| 2024-10-11 | +1.08 % |
|
| 2024-10-10 | +0.38 % |
|
| 2024-10-09 | +0.42 % |
- ResMed Inc. (RMD) stock increased by 0.42% following a recent transaction where CEO Michael J. Farrell sold shares, which may have contributed to investor confidence alongside positive growth in earnings and quarterly dividends, coupled with optimistic analyst price targets.
- ResMed Inc. (NYSE:RMD) stock rose by 0.42% after the CFO sold 1,000 shares at $233.47 each, indicating strong investor confidence in the company's performance and prospects, as evidenced by its recent earnings beat and dividend increase.
- ResMed Inc. (NYSE:RMD) experienced a 0.42% increase in its stock price, potentially influenced by the CEO's sale of shares, which may indicate confidence in the company's financial standing.
- ResMed Inc. (NYSE:RMD) saw a 0.42% increase in stock price following the CEO's sale of shares, which did not significantly impact his overall holdings, and the company continued to receive positive analyst sentiments and price target upgrades, contributing to investor confidence.
|
| 2024-10-07 | -0.72 % |
|
| 2024-10-04 | -1.87 % |
|
| 2024-10-03 | -0.18 % |
|
| 2024-10-02 | +0.05 % |
|
